Active ingredientOritavancinCat. No. P-O030-001CAS 171099-57-3Family · Pharmaceutical analytical standards
Oritavancin
A semi-synthetic lipoglycopeptide antibiotic, developed in the 1990s and approved in 2014 in the United States and in 2015 in Europe for acute bacterial skin infections: a single intravenous infusion covers the whole course of treatment. This family brings together the active ingredient.
Did you know?It is derived from chloroeremomycin, a natural vancomycin-like glycopeptide made by the bacterium Amycolatopsis orientalis, which on its own has never been used in medicine.
Go to the active ingredient →Active ingredientOritavancinCat. No. P-O030-001CAS 171099-57-3
Active ingredientOritavancin PhosphateCat. No. P-O030-002CAS 192564-14-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.